Stock Research for CELG

CELG

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CELG Stock Chart & Research Data

The CELG chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CELG chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CELG Due diligence Resources & Stock Charts

The CELG stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CELG Detailed Price Forecast - CNN Money CNN View CELG Detailed Summary - Google Finance
Yahoo View CELG Detailed Summary - Yahoo! Finance Zacks View CELG Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CELG Trends & Analysis - Trade-Ideas Barrons View CELG Major Holders - Barrons
NASDAQ View CELG Call Transcripts - NASDAQ Seeking View CELG Breaking News & Analysis - Seeking Alpha
Spotlight View CELG Annual Report - CompanySpotlight.com OTC Report View CELG OTC Short Report - OTCShortReport.com
TradeKing View CELG Fundamentals - TradeKing Charts View CELG SEC Filings - Bar Chart
WSJ View Historical Prices for CELG - The WSJ Morningstar View Performance/Total Return for CELG - Morningstar
MarketWatch View the Analyst Estimates for CELG - MarketWatch CNBC View the Earnings History for CELG - CNBC
StockMarketWatch View the CELG Earnings - StockMarketWatch MacroAxis View CELG Buy or Sell Recommendations - MacroAxis
Bullish View the CELG Bullish Patterns - American Bulls Short Pains View CELG Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CELG Stock Mentions - StockTwits PennyStocks View CELG Stock Mentions - PennyStockTweets
Twitter View CELG Stock Mentions - Twitter Invest Hub View CELG Investment Forum News - Investor Hub
Yahoo View CELG Stock Mentions - Yahoo! Message Board Seeking Alpha View CELG Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CELG - SECform4.com Insider Cow View Insider Transactions for CELG - Insider Cow
CNBC View CELG Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CELG - OTC Markets
Yahoo View Insider Transactions for CELG - Yahoo! Finance NASDAQ View Institutional Holdings for CELG - NASDAQ


Stock Charts

FinViz View CELG Stock Insight & Charts - FinViz.com StockCharts View CELG Investment Charts - StockCharts.com
BarChart View CELG Stock Overview & Charts - BarChart Trading View View CELG User Generated Charts - Trading View


Latest Financial News for CELG

3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018
Posted on Sunday July 15, 2018

Forget what's happened so far in 2018. These big pharma stocks look like great picks for the rest of the year.


Why Celgene Corporation Lost 23.9% of Its Value Halfway Through 2018
Posted on Friday July 13, 2018

Celgene's self-inflicted wounds haven't sat well with investors this year.


Biotech Celgene's Stock Seen Rebounding 14%
Posted on Friday July 13, 2018

Celgene Corp.'s ( CELG) stock appears to be on the mend, after falling by more than 40% since the middle of October. The biotech company has been working hard in 2018 trying the turn the corner, by making two big acquisitions, helping to strengthen the pipeline. Analysts still see robust growth for the stock, while it also happens to be trading at its lowest valuation since 2015.


Ex-Drug CEO Running for Senate Seat Attacked by Old Industry Foe
Posted on Thursday July 12, 2018

A patient-advocacy group opposed to high drug prices says it will spend $1.5 million on ads attacking New Jersey GOP Senate candidate Bob Hugin, the former chief executive of drugmaker Celgene Corp. The advocacy group, Patients for Affordable Drugs Action, says the anti-Hugin ads that will run in the state are the first of millions of dollars worth of in political advertising it will use to target candidates it says are responsible for high drug prices. In 2007, when Hugin was chief operating officer, a 10-milligram dose of the company’s blockbuster cancer pill Revlimid cost $247.28, according to data from Connecture Inc. Over the next decade, Celgene raised its price more than a dozen times as Hugin became chief executive officer and eventually executive chairman.


Enter a stock symbol to view the stock details.